New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
11:04 EDTFEYE, MFRM, LUK, SBGI, ECYTHigh option volume stocks: FEYE MFRM LUK SBGI ECYT
News For FEYE;MFRM;LUK;SBGI;ECYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTECYTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:28 EDTECYTEndocyte downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Endocyte to Hold saying it views the company's data for vintafolide as "marginal."
September 29, 2014
13:33 EDTSBGISinclair Broadcast enters into long-term affiliation agreements with ABC
Sinclair Broadcast (SBGI) announced that it has entered into long-term agreements with Disney's (DIS) American Broadcasting Company for the renewal of the ABC affiliations in 13 Sinclair markets that come up for renewal during 2014 and 2015. Three of the new agreements will expire on August 31, 2019 and the other 11 will expire on August 31, 2020. The markets being renewed are listed below and include six of Sinclair's ten biggest ABC markets, including five of the top six ABC markets. The company's remaining ABC affiliation agreements do not expire for several years. The company said, "We are pleased to have reached this agreement with ABC to renew these affiliation agreements for 5-year terms including a number of agreements that were not set to expire until 2015."
11:48 EDTSBGISinclair Broadcast syndication agreements a positive, says Wells Fargo
Subscribe for More Information
10:01 EDTSBGISinclair Broadcast unit enters syndication agreements for ASN initiative
Subscribe for More Information
06:27 EDTECYTEndocyte to host conference call
Subscribe for More Information
September 28, 2014
14:12 EDTECYTEndocyte says Phase 2b TARGET trial results show improved survival
Endocyte announced that the small molecule drug conjugate, SMDC, vintafolide in combination with docetaxel extended overall survival for patients with folate receptor positive recurrent non-small cell lung cancer, NSCLC, compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress, ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.
September 26, 2014
06:39 EDTFEYEMost connected devices have security flaw, NY Times says
Subscribe for More Information
September 24, 2014
15:04 EDTLUKGoldman, other banks near deal to buy Bloomberg messaging alternative, WSJ says
Subscribe for More Information
13:38 EDTLUKLeucadia decies to cease development of Lake Charles clean energy project
Subscribe for More Information
06:42 EDTMFRMMore e-commerce start-ups undercutting established firms, NY Times says
Subscribe for More Information
September 19, 2014
07:46 EDTFEYEFireEye well-positioned to increase share, says Wells Fargo
After viewing a webinar on FireEye's product initiatives, Wells Fargo thinks the initiatives will probably generate minimal revenue over the next 6-12 months, but leave the company well-positioned to take an increasing share of the total cyber security market. The firm keeps an Outperform rating on the shares.
07:31 EDTMFRMTempur, Mattress Firm weakness would be buying opportunity, says Piper
Subscribe for More Information
07:13 EDTFEYEFireEye price target raised to $40 from $36 at Piper Jaffray
Subscribe for More Information
September 18, 2014
15:41 EDTFEYEFireEye lays out details of new 'FireEye as a Service' offering
Reference Link
September 17, 2014
15:12 EDTFEYEFireEye September volatility elevated into webinar to discuss new services
Subscribe for More Information
09:02 EDTFEYELilien Systems, FireEye announce partnership
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use